Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Nagpur Unit-1 manufacturing facility that manufactures oral solid dosage forms. The EIR was issued post the last inspection of the facility conducted in July 2023. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
